XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
BMC Cancer. 2008 Nov 12;8:332. doi: 10.1186/1471-2407-8-332. BMC Cancer. 2008. PMID: 19014494 Free PMC article. Clinical Trial.